

Patent Selections:

The patents annotated in this section have been selected from various patent collections. They are recent patents categorized by therapeutic area / agent / target and therapeutic agents related to central nervous system drug discovery and are relevant to the articles published in this journal issue.

GALANTHAMINE DERIVATIVES AND ANALOGS

1. Baroni, M., Cardamone, R., Fournier, J., Guzzi, U., Ielmini, A. Use of benzoylalkyl-1, 2, 3, 6- tetrahydro-pyridines *US6936621 (2005)*.
2. Moormann, J., Mucke, H., Opitz, K. Active Ingredient Combination (e.g. Galanthamine or desoxypeganine with acamprosate or memantine for treating a dependence on addictive substances or narcotics *PL0367207A1 (2005)*.
3. Optiz, K., Moormann, J., Hille, T., Becher, F. Utilization of galanthamine for the treatment of pathologies of the central nervous system owing to intoxications with psychotropic substances *PL0366840A1 (2005)*.
4. Thal, C., Guillou, C., Beunard, J.-L., Gras, E., Potier, P. Total synthesis of galanthamine, analogs and derivatives thereof *US20050065338A1 (2005)*.
5. Gilis P.M.V., De Conde, V.F.V. Tablet comprising as an active ingredient a therapeutically effective amount of galanthamine hydrobromide and process of its preparing *SK0284620B6 (2005)*.
6. Hille, T., Hoffmann, H.R., Kreh, M., Matusch, R. Process for isolating and pharmaceutical preparation in which galanthamine is comprised *CZ0294722B6 (2005)*.
7. Bonnie, D. Analogs of galanthamine and lycoramine as modulators of nicotinic receptors *AU0780012B2 (2005)*.
8. Ulrich, J., Johannes, F., Matthias, T., Manfred, H., Laszlo, C., Beate, K., Stefan, W. Novel derivatives and analogs of galanthamine *HK1045990A1 (2005)*.
9. Bodenteich, A., Frantsits, W.J., Pirich, E., Czollner, L. Use of galanthamine and the derivatives thereof in the production of medicaments *W05030332A3 (2005)* and *W05030332A2 (2005)*.
10. Asmussen, B., Moormann, J. Buccal formulations of galanthamine and uses thereof *WO05027870A1 (2005)*.
11. Shair, M., Westwood, N., Pelish, H.E. Alkaloids *US6797819 (2004)*.
12. Thal, C., Guillou, C., Mary, A., Renko, D., Potier, P., Christen, Y. Galanthamine derivatives, preparation method therefor, use thereof as drugs, and pharmaceutical compositions containing such derivatives *EP0839149B9 (2005)*.
13. Thal, C., Guillou, C., Mary, A., Renko, D., Potier, P. Total synthesis of galanthamine, analogs and derivatives thereof *EPI458724A1 (2004)*.
14. Jordis, U., Frelikh, J., Troj, M., Khirnschall, M., Tsoll'ner, L., Kel'ts, B., Vel'tsig, S. Derivatives of galanthamine, method for their preparing, medicinal agent based on thereof and method for its preparing *RU2241001C2 (2004)*.
15. Matusch, R., Kreh, M., Hoffmann, H.-R., Hille, T. Process for isolating galanthamine *CA2215351C (2005)*.
16. Moormann, J., Mucke, H., Opitz, K. Active ingredient combination (e.g. Galanthamine or desoxypeganine with acamprosate or memantine) for treating a dependence on addictive substances or narcotics *EPI397138B1 (2005)*.
17. Lundy, Kristin M. Methods for treating age-related behavioral disorders in companion animals *US6951873 (2005)*.
18. Bruinsma, G.B. Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR) 1,3a,8 trimethyl 1,2,3,3a,8,8a hexahydropyrrolo[2,3 b]indol 5 yl phenyl-carbamate *EP1576955A1 (2005)*.
19. Tracey, K.J., Amella, C.A., Czura, C. Neural tourniquet *WO05092308A2 (2005)*.
20. Staubli, U., Lynch, G., Zhong, S., Colgin, L. Enhancement of ampakine-induced facilitation of synaptic responses by cholinesterase inhibitors *WO05072345A2 (2005)*.
21. Koo, E.H.M., Golde, T.E., Galasko, D.R., Weggen, S. Abeta42 lowering agents *US20050186559A1 (2005)*.
22. Friedl, T., Mierau, J., Raschig, A., Reess, J., Scheel-Krueger, J. Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor *US20050154009A1 (2005)*.
23. Acetylcholinesterase inhibitors and *N*-methyl-D-aspartate antagonists useful in the treatment of cognitive disorders *WO05092009A2 (2005)*.
24. Moebius, H.-J., Stöffler, A., McDonald, S., Reisberg, B., Ferris, S.A. 1-Aminocyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with Alzheimer's disease *WO05084655A1 (2005)*.
25. Bruinsma, G. Combinatorial therapy with an acetylcholinesterase inhibitor and (3AR)-1,3a,8-trimethyl-1,2,3,3a, 8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate *WO05079789A1 (2005)*.
26. Maffrand, J.P., Soubrie, P., Terranova, J.P. Combination of active ingredients for the treatment of senile dementia of the Alzheimer type *US2005 0148614A1 (2005)*.
27. Imura, Y., Kosasa, T., Yamanishi, Y. (1-Indanone)-(1,2,3,6-tetrahydropyridine) compounds *US20050124642A1 (2005)*.

28. Rebeck, J.Jr., Pryor, K.E. Glycoluril core molecules for combinatorial libraries *US6939973 (2005)*.
29. Chambers, M.S., Jones, P., MacLeod, A.M., Maxey, R.J., Szekeres, H.J. Nitrogen substituted 1,2,4-triazolo [3,4-a]phthalazine derivatives for enhancing cognition *US6900209 (2005)*.
30. Boyle, C.D., Greenlee, W.J., Chackalamannil, S. Muscarinic antagonists *US6890936 (2005)*.
31. Martinez G.A., Dorransoro D.I., Rubio A.L., Alonso G.D., Fuertes H.A., Morales-Alcelay, S., Del Monte M.M., Garcia P.E., Usan Egea, P., De Austria, C., Medina P.M. Dual binding site acetylcholinesterase inhibitors for the treatment of Alzheimer's disease *EP1558255A2 (2005)*.
32. Moebius, H.-J. Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors *EP1556019A2 (2005)*.

GABA ANALOGS

1. Gallop, M.A., Cundy, K.C., Zhou, C.X., Yao, F., Xiang, J.-N., Ollman, I.R., Qui, F.G. Prodrugs of GABA analogs, compositions and uses thereof *NZ0530109A (2005)*.
2. Barrett, R.W., Canafax, D.M. Treating or preventing restless legs syndrome using prodrugs of GABA analogs *WO05027850A3 and WO05027850A2 (2005)*.
3. Barrett, R.W. Treating and/or preventing urinary incontinence using prodrugs of GABA analogs *WO05025562A1 (2005)*.
4. Barrett, R.W., Canafax, D.M. Treating or preventing restless legs syndrome using prodrugs of GABA analogs *US20050192353A1 (2005)*.
5. Barrett, R.W. Treating and/or preventing urinary incontinence using prodrugs of GABA analogs *US20050090550A1 (2005)*.
6. Schrier, D., Taylor, C.P. Jr., Westlund-High, K.N. Anti-inflammatory method using gamma-aminobutyric acid (GABA) analogs *US6887902 (2005)*.
7. Kulkarni, N.M., Schneider, M., Silbering, S.B., Meyer-Wonnay, H.R., Sanii-Yahyai, N. Stable liquid pharmaceutical composition comprising a GABA analog i.e. gabapentin or pregabalin, and a polyhydric alcohol e.g. glycerol, xylitol, sorbitol, mannitol *NZ0529173A (2005)*.
8. Schrier, D., Taylor, C.P.Jr., Westlund-High, K.N. Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases *EP0994704B1 (2005)*.
9. Kulkarni N., Schneider M., Silbering S., Meyer-Wonnay H., Sanii-Yahyai N. Liquid pharmaceutical composition *BG0108376A (2005)*.
10. Thor, K.B., Burgard, Edward C., Fraser, M.O. Methods of treating non-painful bladder disorders using alpha2delta subunit calcium channel modulators *US20050054725A1 (2005)*.
11. Blazecka, P.G., Davidson, J.G., III, Zhang, J. Process for preparing highly functionalized -butyrolactams and -amino acids *US6924377 (2005)*.
12. Cundy, K.C., Gallop, M.A., Zhou, C.X. Bile-acid conjugates for providing sustained systemic concentrations of drugs *US6900192 (2005)*.
13. Jelley, R.A., Ladduwahetty, T., MacLeod, A.M., Madin, A., Sternfeld, F. Imidazolophthalazine derivatives as ligands for GABAA receptors *US6949549 (2005)*.
14. Carling, W.R., Ladduwahetty, T., MacLeod, A.M., Reeve, A.J., Sternfeld, F. Imidazolophthalazine derivatives as ligands for GABAA receptors *US6946461 (2005)*.
15. Ekwuribe, N.N., Rhadakrishnan, B., Price, C.H., Anderson, W.Jr., Ansari, A.M. Methods for delivering therapeutics across blood-barrier and for altering receptor binding affinity *US6943148 (2005)*.
16. Broom, T., Delpogetto, M., Atkins, R., Negus, A., Oxley, P.W. Pharmaceutically active morpholinol *US6855820 (2005)*.
17. Legarda, I.J.J. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse *US20050192271A1 (2005)*.
18. Bettati, M., Blurton, P., Carling, W.R., Chambers, M.S., Hallett, D.J., Jennings, A., Lewis, R.T., Russell, M.G.N., Street, L.J., Szekeres, H.J., Van Neil, M.B. Imidazo-triazine derivatives as ligands for GABA receptors *US6936608 (2005)*.
19. Goodacre, S.C., Hallett, D.J., Street, L.J. Imidazopyrazine derivatives as ligands for GABA receptors *US6914063 (2005)*.
20. Hallett, D.J., Russell, M.G.N., Street, L.J. Imidazo[1,2-C]pyrimidine derivatives as ligands for GABA receptors *US6914065 (2005)*.
21. Goodacre, S.C. Imidazo[4,5-c]pyridin-4-one analogues as GABAA receptor ligands *US6887885 (2005)*.
22. Carling, W.R., Mitchinson, A., Russell, M.G., Street, L.J. Pyrazolo-triazine derivatives as ligands for GABA receptors *US6872720 (2005)*.
23. Crawforth, J.M., Goodacre, S.C., Harrison, T., Hallett, D.J., Owens, A.P., Rowley, M., Teall, M.R. Imidazopyridine derivatives as ligands for GABA receptors *US6872731 (2005)*.
24. Goodacre, S.C. Imidazotriazinone derivatives as ligands for GABA receptors *US6914060 (2005)*.
25. Chambers, M.S., Goodacre, S.C., Hallett, D.J., Jennings, A., Jones, P., Lewis, R.T., Moore, K.W., Russell, M.G.N., Street, L.J., Szekeres, H.J. Imidazo-pyrimidine derivatives as ligands for GABA receptors *US6900215 (2005)*.
26. Cotrel, C., Roussel, G. Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it *US6864257 (2005)*.

27. Ait, I.A., Resink, A., Schweighoffer, F. Molecular target of neurotoxicity *US6855736 (2005)*.

DEPRESSION AND ANXIETY DISORDERS

- Gharagozloo, P., Islam, K., Kyle, D.J., Sun, Q., Tafesse, L., Whitehead, J.W.F., Yang, J., Zhou, X. Therapeutic agents useful for treating pain *US6864261 (2005)*.
- Baker, R., Curtis, N.R., Elliott, J.M., Harrison, T., Hollingworth, G.J., Jackson, P.S., Kulagowski, J.J., Rupniak, N.M., Seward, E.M., Swain, C.J., Williams, B.J. Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety *EP0941093B1 (2005)*.
- Huet De Barochez, B., Wuethrich, P. Matrix Tablet allowing the prolonged release of the sodium salt of tianeptine and process for the preparation thereof *HU0224192B1 (2005)*.
- Ray, A. K., Evertsson, E.M., Linusson J.A.S.M., Sandberg, P.M., Inghardt, T., Svensson H.A.M., Brickmann, K. MCHR antagonists *EP1528924A1 (2005)*.
- Bruns, R.F. Jr., Cooper, R.D.G., Dressman, B.A., Hunden, D.C., Kaldor, S.W., Koppel, G.A., Rizzo, J.R., Skelton, J.J., Steinberg, M.I. Non-peptidyl vasopressin V1a antagonists *EP0939632B1 (2005)*.
- Bryans, J.S., Johnson, P.S., Roberts, L.R., Ryckmans, T. Compounds useful in therapy *US20050154024A1 (2005)*.
- Guillon, C.D.G., Heindel, N.D., Koppel, G.A., Miller, M.J. 3-Substituted -lactamyl vasopressin V1a antagonists *WO05035492A1 (2005)*.
- Koppel, G.A., Hunden, D.C., Skelton, J.J., Kaldor, S.W., Steinberg, M.I., Rizzo, J.R., Bruns, R.F.Jr., Cooper, R.D.G., Dressman, B.A. Non-peptidyl vasopressin V1A antagonists *CA2246753C (2005)*.
- Stiernet, F., Genicot, C., Lassoie, M.-A., Moureau, F., Ryckmans, T., Taverne, T., Henichart, J.-P., Neuwels, M., Goldstein, S. -Arylethylpiperazine derivatives as neurokinin antagonists *US6916797 (2005)*.
- Hu, M. Pharmaceutical compositions *WO05063243A19 (2005)*.
- Sobolov-Jaynes, S.B., Schmidt, C.J., Lebel, L.A. Combinations of PDE-V inhibitors and NK1 antagonists for the treatment of depression *EP1515708A1 (2005)*.
- Parsons, C.G.R., Jirgensons, A., Jauzeme, I., Kalvinsh, I., Henrich, M.Vanejevs, M., Weil, T., Kauss, V., Danysz, W. Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors glycine transporter inhibitors *WO05082856A2 (2005)*.
- Bear, M.F., Huber, K.M., Warren, S.T. Methods of treating disorders with group I mGluR antagonists *US20050171067A (2005)*.
- Froestl, W. Phosphinic acid derivatives *WO05054259A1 (2005)*.

GLYCINE TRANSPORTER INHIBITORS

- Smith, G.P., Andersen, K., Wren, S.P., Harris, N., Brandt, G. Phenyl indan derivatives *WO05087708A1 (2005)*.
- Bicyclic [3.1.0] derivatives as Glycine Transporter Inhibitors *WO05037216A3 (2005)*.
- Lowe, J.A., Mchardy, S. Bicyclic [3.1.0] derivatives as glycine transporter inhibitors *WO05037216A2 (2005)* and *WO05037216A3 (2005)*.
- Lowe, J.A., Mchardy, S. Bicyclic [3.1.0] derivatives as glycine transporter inhibitors *US20050096375A1 (2005)*.
- Dargazanli, G., Estenne, B.G., Magat, P., Marabout, B., Roger, P. New N-heterocyclymethyl benzamide derivatives useful as glycine transporter inhibitors for e.g. treating dementia-associated behavioral problems, psychoses, anxiety, depression and alcohol abuse *FR2861076A1 (2005)*.
- Dargazanli, G., Estenne, B.G., Magat, P. New N-(piperidiny)(phenyl)methyl amide derivatives useful as glycine transporter inhibitors, e.g. for treating dementia-associated behavioral problems, psychoses, anxiety, depression, alcohol abuse *FR2861074A1 (2005)* and *FR2861073A1 (2005)*.
- Ridet, J.-L., Mallet, J. Human adult astrocytes, their preparation and uses thereof *US6943016 (2005)*.
- Blaschuk, O.W., Gour, B.J. Compounds and methods for modulating cell adhesion *US6914044 (2005)*.
- Charette, M.F., Ebendal, T., Rueger, D.C. Synergistic effects of OP/BMP morphogens and GDNF/NGF neurotrophic factors *US6936582 (2005)*.
- Horvath, C., Farkas, S., Domany, G., Borza, I., Bartane S.G. Nagy, J., Kolok, S. Amide derivatives as NMDA receptor antagonists *US6919355 (2005)*.
- Lukanidin, E., Bock, E.M., Berezin, V. Neurogenic compositions and methods *US6903188 (2005)*.
- Anderson, D.J., Lo, L.-C. Methods and compositions for neural progenitor cells *US6890724 (2005)*.
- Sontheimer, H.W., Ullrich, N. Method of diagnosing and treating gliomas *US6870029 (2005)*.
- Peterson, W.M. Method for treating retinal degeneration with purinergic receptor agonists *US6864243 (2005)*.
- Murphy, B., Boynton, A.L., Sehgal, A., Murphy, G.P. Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis *US6863887 (2005)*.

THERAPEUTICS AND ALZHEIMER'S DISEASE

- Bailey, S., Gautier, E.C.L., Henderson, A.J., Magee, T.V., Marfat, A., Mathias, J.P., McLeod, D.G., Monaghan, S.M., Stammen, B.L.C. Nicotinamide derivatives useful as PDE4 inhibitors *US6949573 (2005)*.

2. Kung, H.F., Kung, M.-P., Zhuang, Z.-P. Amyloid plaque aggregation inhibitors and diagnostic imaging agents *US6946116 (2005)*.
3. Snow, A., Castillo, G. Composition and methods for treating Alzheimer's disease and other amyloidoses *US6939570 (2005)*.
4. Kreft, A.F., Cole, D.C., Woller, K.R., Stock, J.R., Diamantidis, G., Kubrak, D.M., Kutterer, K.M., Moore, W.J., Casebier, D.S. Heterocyclic sulfonamide inhibitors of beta amyloid production *US6878742 (2005)*.
5. Sakai, Y., Nishiura, A., Ogata, T. Endogenous repair factor production promoters *EP1563846A1 (2005)*.
6. Lynch, G., Bi, X. Model for Alzheimer's disease and other neurodegenerative diseases *US6803233 (2005)*.
7. Schenk, D.B. Passive immunization of Alzheimer's disease *US6913745 (2005)* and *US6936246 (2005)*.
8. Schenk, D.B. Prevention and treatment of amyloidogenic disease *US6946135 (2005)*, *US6866850 (2005)* and *US6866849 (2005)*.
9. Schenk, D.B. Active immunization for treatment of Alzheimer's disease *US6905686 (2005)* and *US6923964 (2005)*.
10. St.George-Hyslop, P.H., Fraser, P.E. Proteins related to schizophrenia and uses thereof *US6929919 (2005)*.
11. Schenk, D.B. Active immunization of AScr for prion disorders *US6923964 (2005)* and *US6923964 (2005)*.
12. Schenk, D.B. Pharmaceutical compositions and methods for treatment of amyloid diseases *US6890535 (2005)*.
13. Schenk, D.B. Methods of treatment of Alzheimer's disease *US6875434 (2005)*.
8. Herman, R., Delgado, S.G., Fish, L.M., Sangameswaran, L., Rabert, D.K. Cloned peripheral nerve, tetrodotoxin-resistant sodium channel alpha-subunit *US20050186627A1 (2005)*.
9. Kapeller-Libermann, R. 13245, a novel human myotonic dystrophy type protein kinase and uses therefore *US6946274 (2005)*.
10. Choi, S.-K., Fatheree, P.R., Green, D.C., Marquess, D. Sodium channel modulators *US6872741 (2005)*.
11. Wilson, D.M., Termin, A.P., Neubert, T.D. Condensed pyrimidine compounds as inhibitors of voltage-gated ion channels *WO05014558A1 (2005)*.
12. Wilson, D.M., Martinborough, E., Neubert, T.D., Termin, A.P., Gonzalez, J.E., Zimmerman, N. Pyrimidines useful as modulators of voltage-gated ion channels. *US20050049247A (2005)*.
13. Wilson, D.M., Termin, A.P., Martinborough, E., Zimmerman, N. Compositions useful as inhibitors of voltage-gated sodium channels *US20050137190A1 (2005)*.
14. Gonzales, J.E.III, Termin, A.P., Martinborough, E., Zimmerman, N. Compositions useful as inhibitors of voltage-gated sodium channels *WO05013914A2 (2005)*.

CAPSAICIN ANALOGUES

1. Campbell, J.N., Pappagallo, M., Meyer, Richard A. Compositions containing capsaicin or capsaicin analogues and a local anesthetic *EP0998288B2 (2005)*.
 2. Pappagallo, M., Meyer, R.A., Campbell, J.N. Compositions containing capsaicin or capsaicin analogues and a local anesthetic *CA2285203C (2005)*.
 3. Julius, D.J., Caterina, M.J., Brake, A.J. Nucleic acid sequences encoding capsaicin receptor and capsaicin receptor-related polypeptides and uses thereof *US20050095650A1 (2005)*.
 4. Eisele, F. Neutral electrode for HF surgery *WO05087124A1 (2005)*.
 5. Bakthavatchalam, R., Blum, C.A., Briemann, H., Caldwell, T.M., Cortright, D.N., Hodgetts, K.J., Peterson, J.M., Zheng, X. 4-Amino (aza) quinoline derivatives as capsaicin receptor agonists *WO05042498A3 (2005)*.
 6. Bakthavatchalam, R., Blum, C.A., Briemann, H., Caldwell, T.M., Cortright, D.N., Hodgetts, K.J., Peterson, J.M., Zheng, X. Capsaicin receptor agonists *WO05042498A2 (2005)*.
 7. Bakthavatchalam, R., Blum, C.A., Briemann, H., Darrow, J.W., De Lombaert, S., Yoon, T., Zheng, X. Substituted biaryl-4-carboxylic acid arylamide analogs as capsaicin receptor modulators *EP1575918A2 (2005)*.
 8. Lee, C.-H., Bayburt, E.K., Di Domenico, S. Jr., Drizin, I., Gomtsyan, A.R., Koenig, J.R., Perner, R.J., Schmidt, R.G. Jr., Turner, S.C., White, T.K., Zheng, G.Z. Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor *US6933311 (2005)*.
- VOLTAGE -GATED SODIUM CHANNEL BLOCKERS**
1. Hogenkamp, D.J., Nguyen, P., Yang, J. Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof *US6919363 (2005)*.
 2. Reff, M.E., Kloetzer, W.S., Nakamura, T. Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics *US6893636 (2005)*.
 3. Tarleton, R.L., Garg, N. Prophylactic and therapeutic immunization against protozoan infection and disease *US6875584 (2005)*.
 4. Noda, M., Watanabe, E. Nav2 channel gene-deficient mice *US6933422 (2005)*.
 5. Wood, J.N., Akopian, A.N. Ion channel *US20050221394A1 (2005)*.
 6. Wilson, D.M., Termin, A.P., Gonzalez, J.E.III, Zimmermann, N., Zhang, Y., Fanning, L.T.D. Benzimidazoles useful as modulators of ion channels *US20050209282A1 (2005)*.
 7. Wilson, D.M., Termin, A.P., Neubert, T.D., Wang, J., Zhang, Y., Gonzalez, J.III, Martinborough, E., Zimmerman, N. Compositions useful as inhibitors of voltage-gated ion channels *US20050187217A1 (2005)*.

9. Bakthavatchalam, R., Blum, C.A., Briemann, H., Caldwell, T.M., De Lombaert, S., Hodgetts, K.J., Zheng, X. Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators **WO04055004C1 (2005)** and **EP1569925A1 (2005)**.
10. Bakthavatchalam, R., Blum, C.A., Briemann, H., Caldwell, T.M., De Lombaert, S., Hodgetts, K.J., Zheng, X. 2-substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators **EP1569925A1 (2005)**.
11. Hackos, D., Serafini, T., Orike, N. VR1 receptors and uses thereof **WO05087807A1 (2001)**.
12. Eade, D.W. Repellent preparations **WO05027642A1 (2005)**.
13. Bakthavatchalam, R., Blum, C.A., Chenard, B.L. 4 - Heterobicyclamino - substituted quinazolines and analogues thereof as capsaicin - antagonists **WO05023807A3 (2005)**.
14. Turkel, C.C., Brin, M.F. Methods for treating headache **US20050191321A1 (2005)**.
15. Vassel, E.J., Nunan, S.C. Non-lethal projectile systems **US20050188886A1 (2005)**.
16. Burch, R.M., Carter, R.B., Lazar, J. Infiltration of capsaicin into surgical sites and open wounds **US20050020690A1 (2005)**.
17. Krumhar, K.C. Method for treatment of inflammation and pain in mammals **US6949260 (2005)**.
18. Auernhammer, C.J., Melmed, S. Transgenic expression from a SOCS-3 promoter in vertebrate cells **US6943018 (2005)**.
19. Ferrone, S., Tsao, C.-Y., Wang, X., Luo, W., Cheung, N.-K.V. GD2 peptide mimics **US6939948 (2005)**.
20. Wei, E.T. 1,2,3,6-tetrahydropyrimidine-2-one compositions, articles and therapeutic methods for upper airway breathing disorders **US6933301 (2005)**.
21. Bleisch, T.J., Castano M.A.M., Dominguez-Manzanares, E., Escribano, A.M. Excitatory amino acid receptor antagonists **US6924294 (2005)**.
22. Wei, E.T. Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith **US6919348 (2005)**.
23. Livi, G.P., Shelton, C. *Caenorhabditis elegans* chemosensory bioassay for seven transmembrane receptor ligands **US6909029 (2005)**.
24. Becerra, L.R., Breiter, H.C., Borsook, D. Method and apparatus for objectively measuring pain, pain treatment and other related techniques **US6907280 (2005)**.
25. Young, P.E., Ruben, S.M. Vanilloid receptor-2 **US6906178 (2005)**.
26. McIntyre, P., James, I.F. Vanilloid receptor **US6887978 (2005)**.
27. Kurakata, S., Hanai, M., Kanai, S., Kimura, T. Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia **US6887893 (2005)**.
28. Chen, I.J. KMST isoeugenol derivatives and pharmaceutical activity **US6887878 (2005)**.
29. Van E.K., De Bruyn, M.F.L. Aminoalkyl substituted (benzodioxan, benzofuran or benzopyran) derivatives **US6864273 (2005)**.
30. Filla, S.A., Ornstein, P.L. Selective iGluR5 receptor antagonists **US6855823 (2005)**.
31. Bleisch, T.J., Filla, S.A., Ornstein, P.L. Excitatory amino acid receptor antagonists **US6855725 (2005)**.
32. Shalev, A. Administration of anti-inflammatory drugs into the central nervous system **US6853858 (2005)**.
33. Yoshizumi, H., Shirasaka N. Lipid peroxide eliminator, food and medicine composition containing the same, and method for eliminating lipid peroxide **JP2005082493A2 (2005)**.
34. Okajima K., Toda T. Edible composition having promoting activity against production and release of calcitonin gene-associated peptide **JP2005068129A2 (2005)**.
35. Bakthavatchalam, R., Blum, C.A., Briemann, H., Caldwell, T.M., De Lombaert, S., Hodgetts, K.J., Yoon, T., Zheng, X. Substituted quinazolin-4-ylamine analogs as modulators of capsaicin and pharmaceutical compositions thereof **HU0500200AB (2005)**.
36. Iwai, K., Watanabe, T., Tamura, Y., Gawa, S. Capsaicin analogue preparation, useful as agents for combatting obesity, made by reacting a long chain fatty acid or ester with capsaicin in the presence of a lipase **FR2780734B1 (2005)**.
37. Miesenbock, G.A., Zemelman, B.V. Heterologous stimulus-gated ion channels and methods of using same **WO03102156B1 (2005)**.
38. Farley, M.D. Pain Management **US20050142177A1 (2005)**.
39. Jean, D., Cariel, L. Use of a vanilloid as an anti-snoring element **US20050118287A1 (2005)**.
40. Raffa, R., Cowan, A., Tallarida, R. Analgesic and glucosamine compositions **US6900189 (2005)**.
41. Muhammad, N., Jamieson, G., Bley, K.R., Chanda, S. Methods and compositions for administration of TRPV1 agonists **US20050090557A1 (2005)**.
42. Blum, C.A., Zheng, X. Aryl-substituted benzo[d]isothiazol-3-ylamine analogues as capsaicin receptor modulators **WO05009982A3 (2005)**.
43. Chen, W., Ramiya, P.H., Burch, R.M., Carter, R.B., Anderson, T.A., McIlvain, S., Zhang, H. Preparation and purification of synthetic capsaicin **US20050085652A1 (2005)**.
44. Morré, D.M., Morré, D.J. Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof **US6878514 (2005)**.

45. Lee, J.W. Simplified resiniferatoxin analogues as vanilloid receptor agonist showing excellent analgesic activity and the pharmaceutical compositions containing the same *US6872748 (2005)*.

HYPERALGESIA AND CNS

1. Giblin, G.M.P., Jones, H.T., Mason, A.M., Miller, N.D., Roomans, S., Shanahan, S.E., Walker, A.L. Naphthalene derivatives which bind to the EP4 receptor *US6924297 (2005)*.
2. O'Brien, J.S. Compositions for alleviating neuropathic pain with prosaposin receptor agonists *US6849602 (2005)*.
3. Balan, C., Chen, N., Doherty, E.M., Gore, V.K., Norman, M.H., Wang, H.-L. Vanilloid receptor ligands and their use in treatments *WO05077938A1 (2005)*.

MIGLUSTAT AND LYSOSOMAL STORAGE DISORDERS

1. Singh, I. Methods and compositions for the prevention and treatment of inflammatory diseases or conditions *WO05063275A1 (2005)*.

2. Ramaswami, M. Genetically modified somatic cells for sustained secretion of lysosomal proenzymes deficient in lysosomal storage disorders *WO05021716A2 (2005)*.
3. Blazar, B., Tolar, J., Verfaillie, C.M. Compositions and methods for the treatment of lysosomal storage disorders *WO05056026A1 (2005)*.
4. Kakkis, E.D. Delivery of therapeutic compounds to the brain and other tissues *WO05021064A3 (2005)*, *WO05021064A2 (2005)* and *US20050048047A1 (2005)*.
5. Aerts, J.M.F.G. Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors *WO05040118A (2005)*.
6. Meikle, P.J., Hopwood, J.J., Winchester, B.G. Diagnosis of lysosomal storage disorders using saposins and other markers *US20050142590A1 (2005)*.
7. Matsui, H., Watanabe, T. Preventives/Remedies for neurodegenerative diseases *EP1536011A1 (2005)*.